# Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

> **NCT05368051** · — · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** long course radiotherapy + capecitabine + PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05368051
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368051, "Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05368051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*